Prognostic implication of TERT promoter mutation and circulating tumor cells in muscle-invasive bladder cancer

Purpose Current clinical prognostic factors are not accurate enough to identify and monitor those muscle-invasive bladder cancer (MIBC) patients at high risk of progression after radical cystectomy (RC). Here, we determined genetic alterations in the tumor and circulating tumor cell (CTC) enumeratio...

Full description

Saved in:
Bibliographic Details
Published in:World journal of urology 2022-08, Vol.40 (8), p.2033-2039
Main Authors: Carrasco, Raquel, Ingelmo-Torres, Mercedes, Gómez, Ascensión, Roldán, Fiorella L., Segura, Natalia, Ribal, María José, Alcaraz, Antonio, Izquierdo, Laura, Mengual, Lourdes
Format: Article
Language:English
Subjects:
Biomarkers
Bladder cancer
Cancer
Enumeration
Invasiveness
Medical prognosis
Medicine
Medicine & Public Health
Mutation
Nephrology
Next-generation sequencing
Oncology
Original
Original Article
Patients
Tumor cells
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Current clinical prognostic factors are not accurate enough to identify and monitor those muscle-invasive bladder cancer (MIBC) patients at high risk of progression after radical cystectomy (RC). Here, we determined genetic alterations in the tumor and circulating tumor cell (CTC) enumeration to find biomarkers useful for the management of MIBC after RC. Methods Thirty-nine MIBC patients undergoing RC were included. Tumoral tissue DNA was analyzed by next generation sequencing. CTCs were isolated from blood collected before RC and one, four and 12 months later. Results Sixteen (41%) patients progressed in a median time of 8.5 months and 11 (69%) of these patients harbored the TERT c.-124C > T mutation. All progressive patients harboring the TERT c.-124C > T mutation presented a significant increase in CTC number 12 months after RC compared to those without the mutation. Additionally, CTC number at 12 months was identified as an independent prognostic biomarker for tumor progression and cancer specific survival (CSS). Ten (63%) progressive patients showed an increment of CTC number with a median anticipation period of four months compared with imaging techniques. Conclusions The TERT c.-124C > T mutation could be considered a biomarker of aggressivity. CTC enumeration is a useful tool for identifying MIBC patients at high risk of progression and CSS after RC and for detecting tumor progression earlier than imaging techniques.
ISSN:1433-8726
0724-4983
1433-8726
DOI:10.1007/s00345-022-04061-9